Search results
Showing 166 to 180 of 433 results for cardiovascular disease
NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .
This quality standard covers treating and managing psychosis and schizophrenia in adults (aged 18 and over) in primary, secondary and community care. It also includes support for the families and carers of people with psychosis or schizophrenia. It describes high-quality care in priority areas for improvement.
View quality statements for QS80Show all sections
Sections for QS80
- Quality statements
- Quality statement 1: Referral to early intervention in psychosis services
- Quality statement 2: Cognitive behavioural therapy
- Quality statement 3: Family intervention
- Quality statement 4: Treatment with clozapine
- Quality statement 5: Supported employment programmes
- Quality statement 6: Assessing physical health
- Quality statement 7: Promoting healthy eating, physical activity and smoking cessation
This indicator covers the proportion of adults with diabetes who have received all 9 basic care processes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG13
This guideline covers improving oral health by developing and implementing a strategy that meets the needs of people in the local community. It aims to promote and protect people’s oral health by improving their diet and oral hygiene, and by encouraging them to visit the dentist regularly.
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)
Evidence-based recommendations on prasugrel (Efient) with percutaneous coronary intervention for treating acute coronary syndromes in adults.
This indicator covers the percentage of patients with diabetes with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes or previous ulcer) or 4) ulcerated foot within the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM13
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)
Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)
Evidence-based recommendations on tafamidis (Vyndaqel) for treating transthyretin amyloidosis with cardiomyopathy in adults.
Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)
Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth hormone deficiency in adults.
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.
Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making
Chronic heart failure in adults: diagnosis and management (NG106)
This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.
Percutaneous radiofrequency ablation for atrial fibrillation (HTG110)
Evidence-based recommendations on percutaneous radiofrequency ablation for atrial fibrillation. This involves inserting a catheter into the heart that produces heat to damage the nerves in the area with the abnormal elecritcal impulses.
View recommendations for HTG110Show all sections
Sections for HTG110
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)
Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.
Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction (HTG297)
Evidence-based recommendations on percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction. This involves implanting a replacement valve with a wire mesh tube called a stent.
View recommendations for HTG297Show all sections
Sections for HTG297